Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

QTc Interval of Healthcare Workers from India: Baseline and Effect of Hydroxychloroquine Prophylaxis during the COVID-19 Pandemic

Gutte et al., Indian Journal of Community Medicine, doi:10.4103/ijcm.ijcm_663_22, CTRI/2020/05/025089
May 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Prospective study of 250 healthcare workers in India, showing no signficant change in QTc interval with HCQ prophylaxis.
Gutte et al., 30 May 2023, India, peer-reviewed, 8 authors, trial CTRI/2020/05/025089. Contact: m.gurjar@rediffmail.com.
This PaperHCQAll
QTc Interval of Healthcare Workers from India: Baseline and Effect of Hydroxychloroquine Prophylaxis during the COVID-19 Pandemic
Shreyas Gutte, Prof Mohan Mohan Gurjar, Om Prakash Sanjeev, Dharmendra Bhadauria, Aditya Kapoor, Prabhaker Mishra, Afzal Azim, Banani Poddar
Indian Journal of Community Medicine, doi:10.4103/ijcm.ijcm_663_22
Short Communication IntRoductIon During the recent coronavirus disease 2019 (COVID-19) pandemic, before the availability of vaccine in the year 2020 itself, the National Task Force by the Indian Council of Medical Research (ICMR) recommended the use of hydroxychloroquine (HCQ) as chemoprophylaxis for asymptomatic healthcare workers (HCWs) involved in the care of suspected or confirmed cases of COVID-19 and asymptomatic household contacts of laboratory-confirmed cases. [1] Their recommendation was based on in vitro studies, which found that HCQ is effective against COVID-19. [2, 3] In view of ICMR recommendations, the Indian Heart Rhythm Society (IHRS) proposed a scientific statement for the use of HCQ and strongly discouraged its use for the general public without medical supervision and prescription. [4] As there is a scarcity of known prevalence of QT interval prolongation in nonhospitalized population in general, and none in specific population such as HCWs from India, we conducted this study to assess the baseline-corrected QT (QTc) interval, the incidence of prolonged QTc interval, and changes, if any, among HCWs taking HCQ prophylaxis while managing COVID-19-confirmed or COVID-19-suspected cases. Methods This was a prospective observational study conducted at a tertiary care university hospital in North India, after approval from the Background: The aim of this study was to access the incidence of prolonged QTc interval and changes, if any, among Indian healthcare workers (HCWs) taking hydroxychloroquine (HCQ) prophylaxis while managing coronavirus disease 2019 (COVID-19) cases. Methods: At the beginning of the COVID-19 pandemic, as per the Indian Council of Medical Research (ICMR) policy, HCWs were advised to take HCQ as prophylaxis after getting an electrocardiogram (ECG) while being posted to look after COVID-19 patients. A follow-up ECG was repeated for those who took HCQ. The normal upper limit for QTc interval of 460 milliseconds (ms) for females and 450 ms for males was considered. Results: A baseline ECG was analyzed for 250 HCWs with a median age of 35 (30-43) years. The median QTc was 410 (395-421) ms with the prevalence of prolonged QTc of 1.8% in females and 0% in males. A follow-up ECG after HCQ intake for 43 HCWs was further analyzed. They had a median age of 35 (31-39) years and took an average dose of HCQ of 2372 ± 839 mg. Pre-and post-HCQ chemoprophylaxis QTc interval (ms) was as follows: 408 (386-419) and 405 (387-417), with P = 0.434, respectively. Conclusion: Among Indian HCWs, the prevalence of prolonged QTc is 1.8% and 0% in females and males, respectively. HCQ intake as chemoprophylaxis for COVID-19 did not affect their QTc interval.
Conflicts of interest There are no conflicts of interest.
References
Agstam, Yadav, Kumar-M P, Gupta, Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis, Indian Pacing Electrophysiol J
Jha, Batra, Siddiqui, Yadav, Misra et al., HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers, Indian Heart J
Jiménez-Jáimez, Macías-Ruiz, Bermúdez-Jiménez, Rubini-Costa, Ramírez-Taboada et al., Absence of relevant QT interval prolongation in not critically ill COVID-19 patients, Sci Rep, doi:10.1038/s41598-020-78360-9
Kapoor, Pandurangi, Arora, Gupta, Jaswal et al., Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society, Indian Pacing Electrophysiol J
Kelley, Preacher, On effect size, Psychol Methods
Leotta, Maule, Rabbia, Colle, Tredici et al., Relationship between QT interval and cardiovascular risk factors in healthy young subjects, J Hum Hypertens
Ma, Li, Guo, Guo, Yu et al., Prevalence and risk factors of prolonged corrected QT interval in general Chinese population, BMC Cardiovasc Disord
Magodoro, Albano, Muthalaly, Koplan, North et al., Population prevalence and correlates of prolonged QT interval: Cross-sectional, population-based study from rural Uganda, Glob Heart
Oscanoa, Vidal, Kanters, Romero-Ortuno, Frequency of long QT in patients with SARS-CoV-2 infection treated with hydroxychloroquine: A meta-analysis, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106212
Rautaharju, Surawicz, Gettes, Bailey, Childers et al., AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society, J Am Coll Cardiol
Roy, Naidu, Raju, Kumar, Rani et al., Evaluation of QT interval in healthy adult males, Indian J Pharmacol
Sogut, Can, Guven, Kaplan, Ergenc et al., Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study, Am J Emerg Med
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1186/1743-422X-2-69
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit